Suntory Limited

Fujisawa Pharmaceutical Company, Ltd.

Daiichi Suntory Pharma Co., Ltd.

Asubio Pharma Co. Ltd.

Fostex Corporation of Japan

Astellas Pharma Gmbh

Shigeki Tamura

Takashi Saitoh

Hirokazu Annoura

Kyoko Nakanishi

Satoshi Ueda

Yukihiro Nomura

Takeo Hirose

Toshio Ideno

Atsuko Fukunaga

Toshio Tatsuoka

Fumio Shimojo

Rinta Ibuki

Kazunari Yamashita

Norio Inomata

Eiji Hashimoto

Mayumi Uesugi

Takahiro Yamagishi

Shinsuke Matsuki

Nobuya Matsumoto

Shinichi Kunisaki

Hiroaki Kitamura

Takeo Chayamachi 525 Hirose

A sustained-release formulation is provided comprising a solid dispersion composition comprising a tricyclic compound or a pharmaceutically acceptable salt thereof in a mixture comprising a water-soluble polymer and a water-insoluble polymer, and an excipient.

Sustained-release formulation

A compound having the formula (I) or its salt, hydrate, hydrate salt or solvate: wherein Rto Rindependently represent H, halogen, OH, alkoxy, optionally substituted alkyl, aryl, or aralkyl group, Rrepresents H, optionally substituted alkyl, aryl, or aralkyl group, Erepresents O, S, or &#x2014;NR, where Rrepresents H, an optionally substituted alkyl, aryl, or aralkyl group, Erepresents O, S, or &#x2014;NR, where Rrepresents H, an optionally substituted alkyl, aryl, or aralkyl group, A represents CH, C(OH), or N, X represents H, halogen, alkoxy, or an optionally substituted alkyl group, and Q represents an optionally substituted phenyl group, phenoxy, phenylmethyl, or cycloalkyloxy group, where when Erepresents O or S, Edoes not represent O or S, which has an action of suppressing the cytotoxic Caoverload and lipid peroxidation and effective for pharmaceutical preparation for the alleviation and treatment of symptoms due to ischemic diseases, etc.

Arylipiperdinopropanol and arylipiperazinopropanol derivatives and pharmaceuticals containing the same

A pharmaceutical composition, especially a pharmaceutical composition for the alleviation or treatment of symptoms due to ischemic diseases and symptoms derived from seizures, epilepsy, and migraine, and a Caoverload suppressant, containing an arylpiperidinol or arylpiperidine derivative having the formula (I): wherein, R is H, an optionally substituted phenyl, an optionally substituted phenoxy, or an optionally substituted benzoyl, A is a connecting bond, a cycloalkylene, or an alkenylene optionally substituted with a lower alkyl, B is an alkylene optionally substituted with OH or an alkoxy or &#x2014;NHCO(CH)&#x2014; where n is an integer of 1 to 5, E is a connecting bond, O, or a methylene, X is OH or H provided that when E is O or a methylene, X is not H, and Y and Z are independently H, a halogen, an alkoxy, or an alkyl optionally substituted with a halogen.

Arylpiperidinol and arylpiperidine derivatives and pharmaceuticals containing the same

The present invention is a method and an apparatus for imaging a liquid-filling container in which a light emitting unit is provided for emitting and irradiating light onto the container and a light receiving unit is provided for receiving the light transmitted through the container. The object of the present invention is to provide such a method and an apparatus for imaging a liquid-filling container. This method and apparatus assures reliable detection of the surface of liquid filled in a container or of foreign substance mixed in the liquid or present in the container or the container material not only when the container is transparent, but also when the container is a colored container of a dark color such as black, dark green or dark brown or the container has a frosted surface of when the liquid filled in the container has a dark color. For accomplishing this object, according to the present invention, the light emitting unit emits near infrared light or the light receiving unit receives near infrared light for imaging the container.

Method and device for imaging liquid-filled container

Sustained release formulation containing tacrolimus or its hydrate is provided. The time (T63.2%) required for 63.2% of the maximum amount of tacrolimus or its hydrate to be dissolved is 0.7 to 15 hours. The time is measured in accordance to the Japanes Pharmacopocia, the 13-th edition, Dissolution Test, No. 2 (Puddles method, 50 rpm) using an aqueous 0.005% hydroxypropyl cellulose solution. This aqueous test solution is adjusted to pH 4.5, accordingly. The formulation further comprises a solid base which is a water-soluble or water-insoluble polymer. The formulation is in the form of a powder, fine powder, granule, tablet or capsule. The formulation is administered to a patient once a day for preventing organ or tissue rejection by transplantation or autoimmune disease. In addition, a solid dispersion composition is provided. The solid dispersion comprises tacrolimus or its hydrate in a mixture containing water-soluble or water-insoluble polymer and an excipient.

Sustained release formulation containing tacrolimus

A compound having the formula (I) or its salt, hydrate, hydrate salt or solvate:wherein Rto Rindependently represent H, halogen, OH, alkoxy, optionally substituted alkyl, aryl, or aralkyl group, Rrepresents H, optionally substituted alkyl, aryl, or aralkyl group, Erepresents O, S, or &#x2014;NR, where Rrepresents H, an optionally substituted alkyl, aryl, or aralkyl group, Erepresents O, S, or &#x2014;NR, where Rrepresents H, an optionally substituted alkyl, aryl, or aralkyl group, A represents CH, C(OH), or N, X represents H, halogen, alkoxy, or an optionally substituted alkyl group, and Q represents an optionally substituted phenyl group, phenoxy, phenylmethyl, or cycloalkyloxy group, where when Erepresents O or S, Edoes not represent O or S, which has an action of suppressing the cytotoxic Caoverload and lipid peroxidation and effective for pharmaceutical preparation for the alleviation and treatment of symptoms due to ischemic diseases, etc.

Arylpiperidinopropanol and arylpiprazinopropanol derivatives and pharmaceuticals containing the same

The present invention relates to a method and an apparatus for imaging a liquid-filling container in which a plurality of imaging devices each comprising a light emitting unit and a light receiving unit are provided. Light from each light emitting unit is irradiated onto a liquid-filling container and this light transmitted through the container is received by each light receiving unit. The object of the present invention is to provide such method and an apparatus for imaging a liquid-filling container. This method or apparatus allows for simultaneous and highly reliable imaging of two or more kinds of condition of the container. For accomplishing this object, according to the present invention, wavelengths of the lights emitted by the respective light emitting units and received by the respective light receiving units of the imaging devices for imaging the liquid-filling containers are different from each other.

Method and device for imaging liquid-filling container

Sustained release formulation containing tacrolimus or its hydrate is provided. The time (T63.2%) required for 63.2% of the maximum amount of tacrolimus or its hydrate to be dissolved is 0.7 to 15 hours. The time is measured in accordance to the Japanese Pharmacopoeia, the 13-th edition, Dissolution Test, No. 2 (Puddle method, 50 rpm) using an aqueous 0.005% hydroxypropyl cellulose solution. This aqueous test solution is adjusted to pH 4.5, accordingly. The formulation further comprise a solid base which is a water-soluble polymer and/or wax. The formulation is in the form of a powder, fine powder, granule, tablet or capsule. Furthermore, the formulation is administered to a patient once a day for preventing organ or tissue rejection by transplantation or autoimmune diseases.

Sustained release formulations containing tacrolimus

Arylpiperidinopropanol and arylpiperazinopropanol derivatives and pharmaceuticals containing the same

Medicament for the alleviation or treatment of symptom derived from the ischemic disease and compound useful thereof

Arylpiperidinol and arylpiperidine derivatives and drugs containing the same

Providing an oral formulation of a macrolide compound where the dissolution of the macrolide compound is under sustained release; and a sustained-release formulation containing a composition in solid solution, where the macrolide compound is present at an amorphous state in a solid base.

Sustained release preparations

An apparatus for dispensing drinking water including of a chamber in which a container packed with drinking water is mounted, a conduit connected with the container in the chamber to dispense drinking water through the apparatus, and sterilizer installed adjacent the conduit means to apply sterilization with substantial heat thereto. The sterilizing means may include automatic control system to control automatically sterilizing with heat. The conduit may includes a storage area for storing drinking water within the conduit, and the storage area may includes two tanks for storing drinking water, one is a cold water tank including a refrigeration device to chill the drinking water, and the other is a hot water tank including heating device to heat the drinking water. The sterilization with heat may be done by heating the conduit with heaters installed surrounding thereof, or may be done by circulating hot water which is stored in the hot water tank through the apparatus. Furthermore, the sterilizer installed adjacent said conduit with the exception of the portions in which hot water is usually passed through in the apparatus during dispensing the drinking water to apply substantial sterilization with heat thereto.

Apparatus for dispensing drinking water

Growing community of inventors

Nara, Japan

Shigeki Tamura